CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. This statistic accounts for medicines treating patients with epilepsy, anxiety, depression, chronic pain, and other illnesses. Legal access does not necessarily equate to financial access. million people.

Access 89

Access Patients Pharmaceutical Education 89

WeedAdvisor

SEPTEMBER 24, 2019

GW Pharmaceuticals created the medication after studies showed surprising success treating severe childhood epilepsy, specifically Lennox-Gastaut Syndrome and Dravet Syndrome. Thanks to the centralized nature of the European Union, this single approval essentially gives all members access to Epidiolex. On June 25, 2018, the U.S.

Epilepsy 49

Epilepsy CBD Pharmaceutical Access 49

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

JULY 6, 2021

It appears most likely to be used for small children with severe myoclonic epilepsy, known as Dravet syndrome. According to the Epilepsy Foundation, Dravet syndome is rare, drug-resistant and leads to prolonged seizures. He said the department had a pharmaceutical products tendering process every two years.

Medicine 81

Medicine Epilepsy Pharmaceutical Access 81

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. Eligible patients were granted access to low-THC marijuana oil. Andrew Turnage, the executive director of the Georgia Access to Medical Cannabis Commission, spoke on this fact.

Oil 98

Oil Patients Access THC 98

The Cannigma

JUNE 1, 2021

Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs. Some of the qualifying health conditions include epilepsy, neuropathic pain, chemotherapy side effects, a need for palliative care, and pain linked to multiple sclerosis, according to France24.

Law 112

Law Epilepsy Programs Patients 112

Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. The industry also encourages the development of novel pharmaceuticals and treatments, creating opportunities for Maryland residents to access cutting-edge healthcare options.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

CannaTech

AUGUST 9, 2018

We are delighted to introduce you to some new friends set to make a big impact on the medical cannabis advocacy scene… the creators of a new documentary called Separating the Strains ; a deeply personal narrative that charts the reality of living with epilepsy, with and without cannabis medication as a treatment option.

Strains 69

Strains Epilepsy Advocacy Medicine 69

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? Yet many people with MS are still unable to access it.”

Treatment 98

Treatment Patients Access Research and Development 98

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. For example, the discovery of CBD’s effectiveness in managing epilepsy led to the development of Epidiolex, the first FDA-approved medication derived from marijuana.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

The Cannigma

JUNE 25, 2022

Patients must have a doctor’s prescription as well as permission from a regional pharmaceutical inspector to obtain cannabis products. Qualifying conditions include chronic pain, multiple sclerosis, spasticity, chemo-induced nausea, and treatment-resistant epilepsy. These products are typically more accessible in larger cities.

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

Cannabis Law Report

DECEMBER 11, 2021

. 'A monumental shame' @AndyMcDonaldMP continuing to highlight how families continue to be passed from pillar to post as the Government fail to continue to tackle the necessary barriers to widen access to life-saving #medicalcannabis prescriptions. He recounted his experience of losing his son to epilepsy. “I Read more at.

Treatment 52

Treatment Access Patients Medicine 52

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon. Notably, 41% of the Cannabis users stopped using opioids altogether.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

For example, many anti-anxiety pharmaceuticals are habit-forming, entail significant negative side effects, and can also cause physical problems such as diminished mobility or coordination. Even doses higher than 1,000mg have been safely administered in testing, and CBD is considered safe for children for the treatment of epilepsy.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Canna Care Docs

SEPTEMBER 18, 2020

Yes, you will be able to upload your records directly to your patient portal which you will receive access to. These bills created the affirmative defense for possession of THC-A oil for the treatment of epilepsy. There can be a total of 5 Pharmaceutical Processors in the state, one for each Health Service area HSA.

Pharmaceutical 98

Pharmaceutical Conditions Patients Oil 98

Veriheal

MAY 17, 2021

Other states have gone beyond just medical access and have also legalized retail cannabis markets for adult consumers. Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” ” State Doctors Oppose Legalization in Alabama.

Legalization 93

Legalization Pharmaceutical Therapy Chronic Pain 93

Veriheal

NOVEMBER 10, 2020

The experiment will allow participating companies to import cannabis and the companies who wish to participate in the experiment will be obliged to give participants free medical cannabis which has to comply with the pharmaceutical standards and good manufacturing practice. .

Chronic Pain 90

Chronic Pain Pharmaceutical Patients Epilepsy 90

Leaf Science

JULY 23, 2019

In the UK, cannabis was legalized for medicinal purposes in 2018 which saw patients of epilepsy and multiple sclerosis able to access pharmaceutical cannabis derivatives such as Sativex and Epidiolex.

Strains 74

Strains Epilepsy Cannabinoids THC 74

Cannabis Law Report

DECEMBER 18, 2019

…MGC Pharmaceuticals has achieved yet another significant milestone with the bio-pharma company this week surpassing more than 1,800 prescribed products of its medicinal cannabis-based pharmaceutical products in Australia, UK, Brazil and Ireland. The West Australian reports. Source: [link].

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

Cannabis Law Report

JULY 24, 2019

But it is important that access to it is delivered in a way that fits in with other treatment options. It has been widely reported in the media that parents with children suffering from intractable epilepsy continue to experience difficulties in securing prescriptions for medical cannabis products containing THC.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

The Cannigma

FEBRUARY 4, 2021

When it comes to cannabis and the struggle for legalization, improving access, and changing hearts and minds, advocates often find themselves up against decades-old myths, misconceptions, and stereotypes that have been delivered from authoritative sources for so long that for many people they supplant the truth. grandbrothers/123rf).

Cannabinoids 145

Cannabinoids THC Blood Pressure Conditions 145

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. For now, if you have access to quality CBD products, there’s no reason to prioritize CBG products. Shutterstock). It’s everywhere. An anti-seizure wonder drug.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Veriheal

AUGUST 9, 2023

CBD, Trema micrantha, and the Study’s Significance CBD means cannabidiol , one of over a hundred compounds in the cannabis plant, and is widely celebrated as a potential treatment for a long list of health concerns, including chronic pain , epilepsy , i nsomnia , anxiety , and skin allergy.

CBD 96

CBD Cannabinoids THC Extraction 96

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Treatment 40

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Chronic Pain 40

SpeedWeed

AUGUST 9, 2021

Argentinian health authorities are now providing access to cannabis derivatives for medicinal, therapeutic and palliative purposes. The first supply of medical cannabis for pediatric patients with epilepsy at the Buenos Aires National Children’s Garrahan Hospital was finally delivered. Shutterstock. It modified Law No.

Epilepsy 52

Epilepsy Research and Development Medicine Patients 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

MMJ Recs

APRIL 1, 2024

Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment. Its non-addictive nature and minimal side effects make it an attractive alternative to conventional pharmaceuticals for many individuals seeking natural remedies.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

FEBRUARY 1, 2022

Medical cannabis and psychedelics are being increasingly recognised by health professionals for their superior safety and efficacy compared to conventional pharmaceuticals. Due to its illegality and stigma, patients greatly suffered from an inability to access this medicine.

Pharmaceutical 52

Pharmaceutical Medicine Safety Epilepsy 52